Curcumin inhibits hypoxia inducible factor-1α-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells

WANXING DUAN1*, YUANHONG CHANG2*, RONG LI1, QINHONG XU1, JIANJUN LEI1, CAIQIAO YIN2, TING LI2, YANZHAO WU2, QINGYONG MA1 and XUQI LI3

1Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710061; 2Department of Gastroenterology, Xi’an No. 4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi 710004; 3Department of General Surgery, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

Received December 12, 2013; Accepted July 1, 2014

DOI: 10.3892/mmr.2014.2551

Abstract. Hepatocellular carcinoma (HCC) accounts for the majority of liver cancers. A hypoxic microenvironment is a common feature of HCC, and is associated with malignant invasion, metastasis and epithelial-mesenchymal transition (EMT) changes. Curcumin is a botanical agent derived from the dried rhizome of Curcuma longa. Although a number of preclinical studies have shown that curcumin has anticancer properties when administered in a normoxic microenvironment, no studies have directly examined the effect of curcumin on preventing HCC invasion and metastasis under hypoxic conditions. This study aimed to determine whether curcumin has effects on the hypoxia-induced malignant biological behavior of HCC. CoCl2 was used to establish a hypoxia model in vitro. The results showed that curcumin significantly decreased hypoxia-induced hypoxia inducible factor-1α (HIF-1α) protein level in HepG2 cells. Furthermore, cell proliferation, migration and invasiveness, as well as EMT changes associated with HIF-1α accumulation generated by a hypoxic microenvironment, were eliminated by curcumin. In conclusion, these data indicate that curcumin may be a viable anticancer agent in the treatment of HCC.

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver malignancy (1). Although the incidence of certain types of cancer have been declining, that of HCC has been increasing worldwide (2,3). In the United States between 1975 and 2005, the 5-year survival rate is <2% in patients with advanced stages of the disease (2). Radical surgery remains the most effective strategy to treat HCC. However, ~70% of patients relapse or develop metastases within 5 years of undergoing this treatment (2). Therefore, more effective interventions for targeting cancer metastasis are required in order to reduce the morbidity and mortality rates associated with HCC.

The initiation of cancer metastasis requires migration and invasion of cells, which is enabled by epithelial-mesenchymal transition (EMT) (4). EMT is a biological process in which epithelial cancer cells in primary tumors lose their cell polarity and cell-cell adhesion, and gain increased migratory and invasive properties in order to become mesenchymal cells. The loss of E-cadherin, the key marker of epithelial cells, is hypothesized to be a crucial event in the initiation of EMT (5). Downregulation of E-cadherin is mediated by overexpression of several EMT-inducing factors, such as snail (6,7). The gain of mesenchymal markers (e.g., vimentin and N-cadherin) is another feature of EMT. Accumulating data have demonstrated a correlation between EMT, and the progression and metastasis of HCC (8,9).

Hypoxia is a common characteristic of solid tumor microenvironments, and is caused by aberrant neovascularization of the rapidly growing tumor mass (10). Evidence indicates that this hypoxic microenvironment can facilitate tumor metastasis (11). The transcription factor hypoxia-inducible factor-1α (HIF-1α), a key mediator of the cellular response to hypoxia, is overexpressed in a wide variety of solid tumors, including HCC (12). HIF-1α consists of an oxygen-dependent degradation domain (ODDD) that mediates oxygen-regulated stability (13). In normoxic conditions, hydroxylation of two proline residues and acetylation of a lysine residue at the ODDD of HIF-1α leads to HIF-1α degradation by the ubiquitin-proteasome pathway. However, under hypoxic conditions, HIF-1α escapes degradation and is stabilized, leading to the expression of a number of target genes.

Curcumin inhibits hypoxia inducible factor-1α-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells

WANXING DUAN1*, YUANHONG CHANG2*, RONG LI1, QINHONG XU1, JIANJUN LEI1, CAIQIAO YIN2, TING LI2, YANZHAO WU2, QINGYONG MA1 and XUQI LI3

1Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710061; 2Department of Gastroenterology, Xi’an No. 4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi 710004; 3Department of General Surgery, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

Received December 12, 2013; Accepted July 1, 2014

DOI: 10.3892/mmr.2014.2551

Abstract. Hepatocellular carcinoma (HCC) accounts for the majority of liver cancers. A hypoxic microenvironment is a common feature of HCC, and is associated with malignant invasion, metastasis and epithelial-mesenchymal transition (EMT) changes. Curcumin is a botanical agent derived from the dried rhizome of Curcuma longa. Although a number of preclinical studies have shown that curcumin has anticancer properties when administered in a normoxic microenvironment, no studies have directly examined the effect of curcumin on preventing HCC invasion and metastasis under hypoxic conditions. This study aimed to determine whether curcumin has effects on the hypoxia-induced malignant biological behavior of HCC. CoCl2 was used to establish a hypoxia model in vitro. The results showed that curcumin significantly decreased hypoxia-induced hypoxia inducible factor-1α (HIF-1α) protein level in HepG2 cells. Furthermore, cell proliferation, migration and invasiveness, as well as EMT changes associated with HIF-1α accumulation generated by a hypoxic microenvironment, were eliminated by curcumin. In conclusion, these data indicate that curcumin may be a viable anticancer agent in the treatment of HCC.

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver malignancy (1). Although the incidence of certain types of cancer have been declining, that of HCC has been increasing worldwide (2,3). In the United States between 1975 and 2005, the 5-year survival rate is <2% in patients with advanced stages of the disease (2). Radical surgery remains the most effective strategy to treat HCC. However, ~70% of patients relapse or develop metastases within 5 years of undergoing this treatment (2). Therefore, more effective interventions for targeting cancer metastasis are required in order to reduce the morbidity and mortality rates associated with HCC.

The initiation of cancer metastasis requires migration and invasion of cells, which is enabled by epithelial-mesenchymal transition (EMT) (4). EMT is a biological process in which epithelial cancer cells in primary tumors lose their cell polarity and cell-cell adhesion, and gain increased migratory and invasive properties in order to become mesenchymal cells. The loss of E-cadherin, the key marker of epithelial cells, is hypothesized to be a crucial event in the initiation of EMT (5). Downregulation of E-cadherin is mediated by overexpression of several EMT-inducing factors, such as snail (6,7). The gain of mesenchymal markers (e.g., vimentin and N-cadherin) is another feature of EMT. Accumulating data have demonstrated a correlation between EMT, and the progression and metastasis of HCC (8,9).

Hypoxia is a common characteristic of solid tumor microenvironments, and is caused by aberrant neovascularization of the rapidly growing tumor mass (10). Evidence indicates that this hypoxic microenvironment can facilitate tumor metastasis (11). The transcription factor hypoxia-inducible factor-1α (HIF-1α), a key mediator of the cellular response to hypoxia, is overexpressed in a wide variety of solid tumors, including HCC (12). HIF-1α consists of an oxygen-dependent degradation domain (ODDD) that mediates oxygen-regulated stability (13). In normoxic conditions, hydroxylation of two proline residues and acetylation of a lysine residue at the ODDD of HIF-1α leads to HIF-1α degradation by the ubiquitin-proteasome pathway. However, under hypoxic conditions, HIF-1α escapes degradation and is stabilized, leading to the expression of a number of target genes.

Correspondence to: Professor Xuqi Li, Department of General Surgery, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi 710061, P.R. China E-mail: lixuqi@163.com

*Contributed equally

Key words: hepatocellular carcinoma, hypoxia, hypoxia inducible factor-1α, epithelial-mesenchymal transition, curcumin
pathway. In hypoxia, the HIF-1α subunit remains stable, accumulates and translocates to the nucleus, where it regulates the expression of target genes. These genes in turn, regulate a variety of cellular processes, such as angiogenesis (14) and EMT (15). Recent evidence suggests that stabilization of the HIF-1α transcription complex, caused by intratumor hypoxia, promotes tumor progression and metastasis (11).

Curcumin is a biological product obtained from the ground rhizomes of *Curcuma longa*, which is a member of the zingiberaceae plant family, and is widely cultivated in Southeast Asian countries (16). Previous studies have demonstrated medicinal qualities, including antiseptic (17), anti-oxidative (18), anti-inflammatory (19), anticoagulative (20) and anti-atherosclerotic (21) properties. Moreover, curcumin has been shown to suppress the transformation, proliferation and metastasis of several types of cancer cells in vivo and in vitro (22). There is extensive literature suggesting that the potential anticancer effects of curcumin may, in part, be mediated through its regulation of various transcription factors, for example nuclear factor (NF)-κB and signal transducers and activators of transcription (23-25). However, previous studies have focused on the effects of curcumin under normoxic conditions. The aim of this study was to determine whether curcumin can inhibit the HIF-1α-associated proliferation, migration, invasion and EMT in HCC in a hypoxic microenvironment, which may more realistically model tumor conditions.

Materials and methods

**Cell culture and cell treatments.** Cells from the human hepatoma cell line, HepG2 (American Type Culture Collection, Rockville, MD, USA), were cultured in Dulbecco’s modified Eagle’s medium (DMEM; HyClone, South Logan, UT, USA) containing 10% fetal bovine serum (FBS; HyClone). Cells were grown in a 5% CO₂ atmosphere at 37°C. To establish hypoxic conditions, the culture medium was supplemented with 10 mol/l CoCl₂ dissolved in ddH₂O (26). Curcumin was dissolved in dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA). The concentration of curcumin (Wako; Tokyo, Japan) in the medium of the HepG2 cells was 10 µmol/l. The cells in the control group were treated with DMSO only, under identical conditions.

**MTT proliferation assays.** To determine the cell proliferation rate, 5,000 cells/well were plated in 96-well plates, cultured for 12 h and then treated with CoCl₂ and curcumin. Cells treated with DMSO served as a control. At indicated time points (24, 48, 72 and 96 h), 20 µl of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) was added to each well and cells were incubated for an additional 4 h at 37°C (27). Following MTT incubation, 150 µl DMSO (Sigma) per well was added to dissolve the crystals. Viable cells were measured by measuring absorbance at 490 nm using a spectrophotometer (Bio-Rad, Hercules, CA, USA).

**Cell scratch-wound assays.** For cell migration assessment, 5x10⁵ cells/well were seeded in 6-well plates and starved for 24 h immediately after cells had reached full confluency. Cells were scratched with a 200 µl pipette tip. Non-adherent cells were removed with phosphate-buffered saline (PBS), and baseline cell layers were photographed (0 h point; Nikon TE300, Tokyo, Japan) and placed into the growth medium. After 24 h, matched-pair wound regions were photographed. The cell migration distance was calculated as the initial scratch width (0 h point) plus the wound healing width (24 h point) (27).

**In vitro invasion assay.** Matrigel invasion assays were performed with 24-well transwell inserts (8 µm; Millipore co., Billerica, MA, USA) as described previously (28). Briefly, the lower surface of the membrane was coated with Matrigel™ (BD Biosciences, Franklin Lakes, NJ, USA). HepG2 cells were pre-treated in a 6-well plate for 24 h and then suspended in the upper chamber in a serum-free medium. Lower compartments were filled with DMEM containing 10% FBS. After 48 h, non-invading cells were gently removed by scraping with a cotton swab, and invading cells in the lower side of the membrane were fixed with 4% paraformaldehyde and stained with crystal violet. The average number of invasive cells in 10 random fields selected on each membrane was calculated using a microscope (x20; Nikon Eclipse TE2000-U; Nikon Instruments, Inc., Melville, NY, USA) in order to quantify the extent of invasion. Each set of experiments was performed in triplicate (29).

**Western blotting.** Western blot analyses were performed as described previously (28). Briefly, total protein was extracted using Mammalian Protein Lysis Buffer (Thermo Scientific Waltham, MA, USA) after each group of cells was treated for 72 h. Equal quantities of protein were added, separated by SDS-polyacrylamide gel electrophoresis and electro-transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). After blocking the membranes with non-fat milk in PBS with Tween-20 (PBST) for 1 h at room temperature, the membranes were incubated with specific primary antibodies overnight at 4°C, and then washed in PBST. The blots were incubated with horseradish peroxidase conjugated-anti-rabbit or anti-mouse monoclonal IgG secondary antibodies (Sigma) at a dilution of 1:10,000 for 1 h. Secondary antibodies were detected by an enhanced chemiluminescence method (Amersham, Piscataway, NJ, USA). The density of specific protein bands

RNA extraction and quantitative polymerase chain reaction (qPCR). Total RNA was extracted from monolayers of cultured HepG2 cells with TRIzol reagent (Invitrogen; Carlsbad, CA, USA). cDNA was synthesized from 5 µg RNA using Takara Reverse Transcription Reagent (Takara, Tokyo, Japan) according to the manufacturer's instructions. The primer sequences were: Forward: 5'-CAAAACACACAGCAAGC-3' and reverse: 5'-TCAACACCGACATCCACC-3' for HIF-1α; forward: 5'-CATCATATCGGCAATGAGC-3' and reverse: 5'-GACAGCATGTGTGCTGCATA-3' for β-actin; forward: 5'-ATTCTGATTCTGCTGCTTGG-3' and reverse: 5'-AGTCTGTGTCCTTTCTCC-3' for E-cadherin; forward: 5'-CTTTCTCTCTACTTCTAGTC-3' for TTC-3' and reverse: 5'-CGTCTGTGTCCTTTCTCC-3' for snail and forward: 5'-AATGACCGGCTTGCAC-3' and reverse: 5'-CCGGACATCTCTCTCGTAG-3' for vimentin.

The following cycling conditions were used: 94°C for 5 sec, 60°C for 30 sec and then 72°C for 30 sec. HIF-1α and β-actin were amplified for 35 cycles. HIF-1α relative expression was analyzed by the comparative C<sub>T</sub> method with β-actin as the normalization control (30).
were determined by Image-Pro Plus 5.0 software (Media Cybernetics, Inc., Rockville, MD, USA). The E-cadherin antibody was purchased from BD Biosciences (San Jose, CA, USA) and mouse monoclonal HIF-1α antibody was purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). The mouse monoclonal β-actin, rabbit monoclonal snail and rabbit polyclonal vimentin antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

**Statistical analysis.** All experiments were repeated at least three times. Results are expressed as the mean ± standard deviation. Differences were evaluated using one-way analysis of variance with the least significant difference post hoc test for multiple comparisons via SPSS (version 15.0; SPSS, Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Curcumin inhibits CoCl2-induced HIF-1α protein expression.** To determine the effect of curcumin on hypoxia-induced HIF-1α expression, HepG2 cells were treated with CoCl2 and curcumin, separately and in combination. The HIF-1α expression was measured by qPCR and western blot analysis. As shown in Fig. 1A, no significant changes were found in the expression of HIF-1α mRNA in HepG2 cells treated with CoCl2 and curcumin, alone or in combination, as compared with the DMSO control group. However, treatment with CoCl2 markedly increased HIF-1α protein levels (Fig. 1B). HIF-1α protein levels were reduced by 70% with curcumin treatment alone compared with the control group. Moreover, accumulation of the HIF-1α protein induced by CoCl2 was prevented by administration of curcumin. These results confirmed that CoCl2 is an effective inducer of HIF-1α at the posttranscriptional level. In addition curcumin appeared to inhibit the HIF-1α protein accumulation induced by CoCl2 without affecting transcription.

**Curcumin inhibits HepG2 cell proliferation.** A previous study demonstrated that CoCl2-induced HIF-1α expression was correlated with enhanced cell proliferation (31). To explore the role of curcumin on proliferation, HepG2 cells were seeded onto 96-well plates, and treated with CoCl2 and curcumin alone or in combination. At the time points indicated in Fig. 2, the proliferative rate of HepG2 cells in each group was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,4-dephenyltetrazolium bromide assay. Data represent the results of three independent experiments. P<0.05 compared with the control group.

**Curcumin inhibits the migration and invasion of HepG2 cells associated with HIF-1α accumulation.** The effect of curcumin on HCC cell motility after CoCl2 treatment was determined using a wound-healing assay. As shown in Fig. 3, the cellular migration of HepG2 cells was significantly reduced by ~30% in the presence of curcumin at each time point measured.

Figure 1. Effect of curcumin on CoCl2-induced HIF-1α expression. (A) Effects of curcumin (10 µmol/l) and/or CoCl2 (10 µmol/l) on mRNA levels of HIF-1α. The mRNA expression of HIF-1α was estimated by qPCR in three groups with β-actin as a normalization control. (B) Immunoblotting results of HIF-1α expression induced by CoCl2 in HepG2 cells after curcumin treatment. Blots were normalized to β-actin protein in each lane. Data represent the results of three independent experiments. Column, mean; bar, standard deviation. HIF-1α, hypoxic inducible factor-1α; qPCR, quantitative polymerase chain reaction.

Figure 2. Effects of curcumin on CoCl2-induced proliferation. HepG2 cells were seeded in a 96-well plate followed by CoCl2 (10 µmol/l) and/or curcumin (10 µmol/l) administration. At the indicated time points, proliferation rates were measured by the 3-(4,5-dimethylthiazol-2-yl)-2,4-dephenyltetrazolium bromide assay. Data represent the results of three independent experiments. Column, mean; bar, standard deviation. *P<0.05 compared with the control group.

Figure 3. Curcumin inhibits the migration and invasion of HepG2 cells associated with HIF-1α accumulation. The effect of curcumin on HCC cell motility after CoCl2 treatment was determined using a wound-healing assay. As shown in Fig. 3A and B, compared with normal controls, HepG2 cells treated with CoCl2 alone exhibited increased migration into the wound area 24 h after wounding occurred. The migration distance...
of cells in the CoCl₂ group was double that of the control group. Cell migration was inhibited by curcumin. In addition, the CoCl₂-enhanced migration of HepG2 cells was reduced by ~40% with curcumin treatment. The migration distance
of cells in the CoCl$_2$ plus curcumin group decreased by 30% compared with that observed in the control group.

Invasiveness was determined by using Matrigel-coated transwell chambers. As shown in Fig. 3C and D, without curcumin intervention, CoCl$_2$ treatment markedly increased the invasiveness of HepG2 cells in comparison with control cells.

As in the wound-healing assay, curcumin significantly inhibited cell invasion. The average number of cells that invaded the lower chamber in the curcumin-treated group was 50% lower than that of the control group. In addition, the enhanced cell invasion observed in the CoCl$_2$ group was also inhibited by curcumin. The number of invasive cells in the CoCl$_2$ plus curcumin group decreased by ~60% compared with that in the CoCl$_2$ group. These results indicate that curcumin inhibits migration and invasion of HCC cells under hypoxic conditions.

**Effects of curcumin on the expression of EMT-related markers induced by HIF-1α in HepG2 cells.** Enhanced cell migration and invasiveness is often linked with EMT. As hypoxia has been shown to induce tumor cell EMT, this study aimed to determine whether curcumin had an effect on EMT markers as measured by qPCR and western blotting. The results showed that in response to CoCl$_2$, HepG2 cells had decreased mRNA expression of the epithelial marker, E-cadherin. However, mRNA expression of the mesenchymal markers, vimentin and snail, increased significantly compared with that in the control cells. Treatment with curcumin markedly diminished the CoCl$_2$-induced downregulation of E-cadherin, and upregulation of vimentin and snail mRNA levels (Fig. 4A). Measurement of protein levels showed similar results (Fig. 4B). These results demonstrated that curcumin suppressed EMT associated with HIF-1α accumulation in HepG2 HCC cells.

**Discussion**

HCC is one of the most common types of malignant disorder, which runs a rapidly progressive clinical course. It is rarely amenable to resection and does not generally respond well to non-surgical treatments, resulting in a poor prognosis (32). The majority of solid tumors, including HCC have been shown to have a hypoxic tumor microenvironment (33). Although hypervascularity and angiogenesis are important features of HCC, due to the increased demand for blood and oxygen supply as a consequence of rapid tumor growth, delivery of oxygen to the tumor is often insufficient.

Recently, evidence from a number of studies has suggested that hypoxic signaling is a central modulator of cellular physiology in cancer cells (34-36). Hypoxia is associated with a poor prognosis in several types of malignancy. Hypoxia-mediated target gene expression has been shown to stimulate proliferation (37), angiogenesis (38), metastasis (39), chemoresistance (40) and radio-resistance (41) of tumor cells. Suppression of tumor cell differentiation (42) and apoptosis (43) has been shown to lead to tumor progression in several types of cancers. Thus, therapeutic strategies aimed at improving the hypoxic intratumor microenvironment, or blocking the signaling pathways activated by hypoxia may be useful in the treatment of solid tumors, including HCC.

It has been well established that HIF-1α is an important transcription factor that is specifically activated during hypoxia. In response to intratumor hypoxia, HIF-1α is stabilized and translocates to the nucleus where it forms a transcriptionally active complex, HIF-1, by coupling to HIF-1β (also termed ARNT) (44). HIF-1 modulates the expression of a number of target genes, the products of which control pathways involved in angiogenesis, cell survival and metastasis (45).

The current study shows that HIF-1α accumulation in HepG2 cells is associated with enhanced migration and invasiveness. In addition, the alteration in levels of EMT-related molecules suggests that cells underwent EMT programming in the hypoxia model induced by CoCl$_2$. This is in agreement with recent studies showing that hypoxia-mediated HIF-1α accumulation leads to β-catenin overexpression in HCC cells, and is accompanied by enhanced invasiveness in *vitro* and metastasis *in vivo* (46). Considering the central role of HIF-1α in hypoxia and the crucial role of HIF-1α in cancer progression, chemotherapeutic agents that target HIF-1α may be attractive modalities to prevent tumor progression.

Research over the last few decades has indicated that curcumin is a potent anti-inflammatory agent with strong therapeutic potential against a variety of types of cancer (22). Extensive studies have demonstrated that curcumin has the ability to suppress transformation, proliferation and metastasis of tumors by regulation of certain molecules involved in cancer progression (16,24,25). The current study found that curcumin alone exhibited antitumor effects under normoxic conditions. In addition, the results indicated that curcumin may also inhibit HCC cell growth, migration and invasion under hypoxic conditions induced by CoCl$_2$. A recent study has shown that curcumin suppresses proliferation and induces apoptosis of human HCC cells in a concentration-dependent manner by inhibiting the Wnt signaling pathway (47). In the current study, the antitumor effect of curcumin was found to be partially mediated by inhibiting HIF-1α stabilization in HepG2 cells, without affecting HIF-1α transcription. These results suggest potential for the treatment of HCC by altering the upregulation of HIF-1α observed in HCC.

In conclusion, the current study indicated that curcumin inhibits hypoxia-induced HIF-1α accumulation in HepG2 cells in a hypoxia model induced by CoCl$_2$. Moreover, curcumin suppresses proliferation, migration, invasion and EMT of HepG2 cells in this environment. These results suggest that curcumin is a potential anticancer agent for the treatment of HCC.

**Acknowledgements**

The authors would like to thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript. This study was financially supported by grants from the National Natural Science Foundation of China (no. 81201824), the Fundamental Research Funds for the Central Universities in Xi’an Jiaotong University (no. 2013jdzh33) and the Scientific Research Program Funded by Shaanxi Provincial Education Department (no. 11JK0704).

**References**

Opinion: migrating

Hypoxia

HIF-2alpha promotes
tumor cell

Curcumin blocks small cell

lung cancer cell migration, invasion, angiogenesis, cell cycle

and neoplasia through Janus kinase-STAT3 signalling pathway.